KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Net Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Net Margin data on record, last reported at 21.74% in Q4 2025.

  • For Q4 2025, Net Margin rose 876174.0% year-over-year to 21.74%; the TTM value through Dec 2025 reached 31.41%, down 3310.0%, while the annual FY2025 figure was 31.41%, 34.0% up from the prior year.
  • Net Margin reached 21.74% in Q4 2025 per REGN's latest filing, down from 38.89% in the prior quarter.
  • Across five years, Net Margin topped out at 43040.28% in Q2 2021 and bottomed at 9677.7% in Q2 2024.
  • Average Net Margin over 5 years is 867.28%, with a median of 26.28% recorded in 2023.
  • Peak YoY movement for Net Margin: surged 4299431bps in 2021, then tumbled -4133608bps in 2022.
  • A 5-year view of Net Margin shows it stood at 21.38% in 2021, then crashed by -7151bps to 1507.9% in 2022, then tumbled by -320bps to 6336.61% in 2023, then plummeted by -38bps to 8740.0% in 2024, then soared by 100bps to 21.74% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 21.74% in Q4 2025, 38.89% in Q3 2025, and 37.86% in Q2 2025.